Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity. With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area. The Director of SEC Reporting and Technical Accounting is an experienced accounting and finance leader that will help build and run SEC reporting processes of our newly public and fast-moving clinical-stage biotechnology company. Reporting to the VP of Finance, this individual will own SEC reporting operations and related internal controls, including the preparation of financial statements and drafting and filing of 10-Qs/10-Ks and annual proxy. This individual will also own technical accounting, including reviewing new contracts for accounting implications and owning the analysis and drafting of technical accounting memos. This is a hands-on role that will collaborate with various internal and external partners, including non-finance operating teams.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
No Education Listed